98%
921
2 minutes
20
The increasing prevalence of gestational diabetes mellitus (GDM) is a pressing global public health concern. Despite extensive identification of GDM risk factors and the implementation of screening programs, there has been a notable lack of significant reduction in maternal, fetal, and neonatal complications. It is vital to recognize that the health trajectory of future generations begins before birth, during intrauterine life and even before conception. The development of 'diabetogenic' and 'obesogenic' changes in the DNA of offspring can be triggered not only by adverse intrauterine conditions, but also by changes in germ cell DNA at earlier stages. Accumulating evidence suggests that the increasing prevalence and persistent metabolic effects of GDM may be mediated by epigenetic modifications. The composition of the human gut microbiota is emerging as a key determinant of human metabolic processes. Consequently, dysbiosis of the gut microbiota via epigenetic mechanisms may contribute to metabolic complications in both the mother and the developing fetus. Given that diet plays a critical role in maintaining a healthy microbiota profile and that certain epigenetic alterations are reversible, it is pertinent to emphasize that not only the pregnant woman but also both partners attempting conception could influence the future health of the child. The aim of this article is to review the role of gut microbiota modulation in preventing and managing gestational diabetes mellitus and the health benefits for mother and child.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12379742 | PMC |
http://dx.doi.org/10.12659/MSM.948897 | DOI Listing |
Brain Behav
September 2025
Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran.
Introduction: Anxiety and stress are prevalent mental health issues. Traditional drug treatments often come with unwanted side effects and may not produce the desired results. As an alternative, probiotics are being used as a treatment option due to their lack of specific side effects.
View Article and Find Full Text PDFChin Med J (Engl)
September 2025
Medical Center of Hematology, Xinqiao Hospital, Army Military Medical University, Chongqing 400037, China.
Folia Microbiol (Praha)
September 2025
Department of Gastroenterology, Chongqing University Cancer Hospital, Chongqing, China.
Microbiome dysbiosis in reflux esophagitis has been extensively studied. However, limited research has examined microbiota across different segments of the upper gastrointestinal tract in reflux esophagitis. In this study, we investigated microbial alterations in three esophageal segments (upper, middle, and lower) and the gastric fundus of reflux esophagitis patients and healthy controls.
View Article and Find Full Text PDFNat Cancer
September 2025
Nature Cancer, .
J Immunother Cancer
September 2025
National Engineering Laboratory for Internet Medical Systems and Applications, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Background: Improving the efficacy of anti-programmed death 1 (PD-1) monoclonal antibody (mAb) therapy remains a major challenge for cancer immunotherapy in non-small cell lung cancer (NSCLC). Gut microbial metabolites can influence immunotherapy efficacy.
Methods: ELISA was used to compare the serum 5-hydroxyindoleacetic acid (5-HIAA) level in patients with NSCLC.